Rebuilding Big Pharma's Business Model

The blockbuster business model that underpinned Big Pharma's success is now irreparably broken: the costs of commercialization are too high and likely returns below the cost of capital. The industry needs a new approach, constructed from four inter-related building blocks--focused R&D; partnerships; customer solutions, not products; and a business unit, not functional, organizational model.

By Jim Gilbert, Preston Henske and Ashish Singh

The pharmaceutical industry is a prisoner of its past successes. While the business environment for pharma companies has changed dramatically...

More from Business Strategy

More from In Vivo